| Primary |
| Product Used For Unknown Indication |
38.4% |
| Herpes Zoster |
11.2% |
| Genital Herpes |
7.3% |
| Prophylaxis |
6.8% |
| Herpes Virus Infection |
5.6% |
| Oral Herpes |
5.4% |
| Chemotherapy |
3.6% |
| Antiviral Prophylaxis |
2.4% |
| Herpes Simplex |
2.4% |
| Acute Leukaemia |
1.9% |
| Pain |
1.9% |
| Lymphoma |
1.7% |
| Multiple Myeloma |
1.7% |
| Coronary Artery Bypass |
1.5% |
| Drug Use For Unknown Indication |
1.5% |
| Graft Versus Host Disease |
1.5% |
| Herpes Ophthalmic |
1.5% |
| Hypertension |
1.5% |
| Hiv Infection |
1.2% |
| Chronic Lymphocytic Leukaemia |
1.0% |
|
| Drug Ineffective |
18.2% |
| Product Substitution Issue |
11.8% |
| Herpes Virus Infection |
7.3% |
| Confusional State |
4.5% |
| Pruritus |
4.5% |
| Pyrexia |
4.5% |
| Therapeutic Response Unexpected With Drug Substitution |
4.5% |
| Toxic Epidermal Necrolysis |
4.5% |
| Agranulocytosis |
3.6% |
| Dizziness |
3.6% |
| Headache |
3.6% |
| Neurotoxicity |
3.6% |
| Oral Herpes |
3.6% |
| Rash Generalised |
3.6% |
| Thrombocytopenia |
3.6% |
| Vomiting |
3.6% |
| Diarrhoea |
2.7% |
| Drug Rash With Eosinophilia And Systemic Symptoms |
2.7% |
| Dysgeusia |
2.7% |
| Nausea |
2.7% |
|
| Secondary |
| Product Used For Unknown Indication |
31.9% |
| Acute Lymphocytic Leukaemia |
10.2% |
| Herpes Zoster |
7.2% |
| Chronic Lymphocytic Leukaemia |
4.9% |
| Hiv Infection |
4.7% |
| Antifungal Prophylaxis |
4.5% |
| Genital Herpes |
4.1% |
| Pyrexia |
4.1% |
| Lung Disorder |
3.7% |
| Hypertension |
3.5% |
| Multiple Myeloma |
3.5% |
| Breast Cancer |
2.9% |
| Depression |
2.7% |
| Acute Leukaemia |
2.5% |
| Prophylaxis |
2.2% |
| Chronic Myeloid Leukaemia |
1.6% |
| Pain |
1.6% |
| Antiviral Prophylaxis |
1.4% |
| Herpes Virus Infection |
1.4% |
| Oral Herpes |
1.4% |
|
| Renal Failure |
8.0% |
| Contusion |
6.9% |
| Drug Ineffective |
6.9% |
| Hepatitis Cholestatic |
6.9% |
| Photosensitivity Reaction |
6.9% |
| Pollakiuria |
6.9% |
| Confusional State |
5.7% |
| Renal Failure Acute |
5.7% |
| Toxic Epidermal Necrolysis |
5.7% |
| Drug Eruption |
4.6% |
| Herpes Virus Infection |
4.6% |
| Toxic Optic Neuropathy |
4.6% |
| Acute Hepatic Failure |
3.4% |
| Aplasia |
3.4% |
| Eosinophilia |
3.4% |
| Erythema Multiforme |
3.4% |
| Muscle Spasms |
3.4% |
| Thrombocytopenia |
3.4% |
| Vomiting |
3.4% |
| Cataract |
2.3% |
|
| Concomitant |
| Product Used For Unknown Indication |
22.7% |
| Prophylaxis |
14.3% |
| Diffuse Large B-cell Lymphoma |
9.8% |
| Multiple Myeloma |
7.6% |
| Infection Prophylaxis |
5.0% |
| Hiv Infection |
4.7% |
| B-cell Lymphoma |
3.7% |
| Aplastic Anaemia |
3.6% |
| Premedication |
3.5% |
| Chronic Lymphocytic Leukaemia |
3.2% |
| Mantle Cell Lymphoma |
3.0% |
| Antiviral Prophylaxis |
2.7% |
| Antifungal Prophylaxis |
2.5% |
| Bone Marrow Conditioning Regimen |
2.5% |
| Hypertension |
2.5% |
| Pain |
2.1% |
| Acute Myeloid Leukaemia |
1.9% |
| Constipation |
1.8% |
| Antibiotic Prophylaxis |
1.5% |
| Prophylaxis Against Graft Versus Host Disease |
1.5% |
|
| Pneumonia |
9.8% |
| Infection |
8.3% |
| Pyrexia |
7.3% |
| Myelodysplastic Syndrome |
5.9% |
| Febrile Bone Marrow Aplasia |
5.4% |
| Pancytopenia |
5.4% |
| Thrombocytopenia |
5.4% |
| Febrile Neutropenia |
4.9% |
| Lung Disorder |
4.9% |
| Sepsis |
4.9% |
| Cytolytic Hepatitis |
4.4% |
| Herpes Simplex |
4.4% |
| Vomiting |
4.4% |
| Weight Decreased |
4.4% |
| Anaemia |
3.4% |
| Diarrhoea |
3.4% |
| Drug Rash With Eosinophilia And Systemic Symptoms |
3.4% |
| Electrocardiogram Qt Prolonged |
3.4% |
| Neuropathy Peripheral |
3.4% |
| Renal Failure |
3.4% |
|
| Interacting |
| Headache |
50.0% |
| Depression |
25.0% |
| Genital Herpes |
25.0% |
|
|
